Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), a biopharmaceutical company focused on advancing innovative therapies and technologies, today provided an update regarding its Investigational New Drug application for Lucid-21-302 (Lucid-MS), the Company's drug candidate for the treatment of multiple sclerosis (MS).